Valuation: Precision Therapeutics Inc

Market Cap 102M 90.94M 83.9M 76.23M 143M 9.65B 145M 1.01B 398M 5.06B 382M 374M 16.02B P/E 2026 *
-4.47x
P/E 2027 * -70.6x
Enterprise Value 102M 90.94M 83.9M 76.23M 143M 9.65B 145M 1.01B 398M 5.06B 382M 374M 16.02B EV / Sales 2026 *
1.69x
EV / Sales 2027 * 0.24x
Free-Float
93.93%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision Therapeutics Inc

Manager TitleAgeSince
Chief Executive Officer 57 09/02/2026
Director of Finance/CFO - 16/04/2026
President - 01/04/2026
Director TitleAgeSince
Director/Board Member 66 19/02/2020
Chairman 78 09/02/2026
Director/Board Member 60 09/07/2020
Change 5-day change 1-year change 3-year change Capi.($)
-7.56%-8.33% - - 102M
-4.10%-8.54%+40.05%+66.99% 63.29B
-0.54%+7.15%+10.64%+72.90% 54.89B
-0.29%+3.71%+9.13%+91.21% 53.28B
+0.61%+2.69%+27.75%+50.97% 45.81B
-1.08%+2.19%+21.92%+131.38% 43.46B
-3.39%-0.83%+254.27%+571.04% 40.23B
-1.67%+6.70%+14.42%+56.67% 33.45B
+1.19%-4.98%+29.01%-0.76% 23.7B
-1.09%+5.12%+35.71%+26.87% 23.76B
Average -1.79%+0.46%+49.21%+118.59% 42.43B
Weighted average by Cap. -1.34%+0.59%+47.34%+122.12%

Financials

2026 *2027 *
Net sales 60.4M 53.91M 49.74M 45.19M 84.77M 5.72B 86.08M 599M 236M 3B 227M 222M 9.5B 431M 385M 355M 323M 605M 40.85B 615M 4.28B 1.69B 21.4B 1.62B 1.58B 67.81B
Net income -41.4M -36.95M -34.09M -30.97M -58.11M -3.92B -59M -411M -162M -2.05B -155M -152M -6.51B -4.5M -4.02M -3.71M -3.37M -6.32M -426M -6.41M -44.64M -17.59M -223M -16.89M -16.53M -707M
Net Debt - -
Logo Precision Therapeutics Inc
Axe Compute Inc. is a virtual neocloud AI infrastructure platform. The Company provides customers with access to graphics processing unit (GPU) compute capacity for artificial intelligence (AI) and other high-performance computing workloads through a distributed network model, including infrastructure made available through the Aethir network. It also operates a digital asset treasury focused on the Aethir token (ATH), the native utility token of the Aethir network. Its segments include Compute Services and Treasury Management and Drug Discovery Services. Its Drug Discovery Services segment provides services that include the application of AI using its proprietary biobank of tumor samples, as well as creation of proprietary 3D culture models used in drug development. The Company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models through two offerings: Axe Compute Access and Axe Compute Build.
Employees
-